Eli Lilly's experimental antibody mirikizumab led to higher rates of clinical response and remission in patients with ulcerative colitis treated in a mid-stage study, which the pharma touted as the first public presentation of data from a IL-23p19 monoclonal antibody in the inflammatory condition.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,